Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 5.7% Higher – Should You Buy?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shot up 5.7% during mid-day trading on Thursday . The company traded as high as $12.14 and last traded at $12.15. 216,635 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 1,503,994 shares. The stock had previously closed at $11.50.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Stock Up 4.5 %

The firm has a market cap of $22.35 million, a P/E ratio of 0.00 and a beta of 2.07. The business’s fifty day moving average price is $29.00 and its two-hundred day moving average price is $24.82. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its earnings results on Tuesday, November 12th. The company reported ($23.00) EPS for the quarter, topping the consensus estimate of ($203.00) by $180.00. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. As a group, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Institutional Trading of Tonix Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $40,000. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $72,000. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals during the 4th quarter valued at about $162,000. Jane Street Group LLC boosted its position in Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after buying an additional 1,635,119 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Tonix Pharmaceuticals by 1,600.1% during the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock worth $650,000 after buying an additional 1,855,907 shares during the last quarter. 82.26% of the stock is currently owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.